Arbutus Biopharma Reports Q2 2025 Revenue Surge to $10.7M, Achieves Net Income of $2.5M, EPS at $0.01

Reuters08-06
<a href="https://laohu8.com/S/ABUS">Arbutus Biopharma</a> Reports <a href="https://laohu8.com/S/QTWO">Q2</a> 2025 Revenue Surge to $10.7M, Achieves Net Income of $2.5M, EPS at $0.01

Arbutus Biopharma Corp., a clinical-stage biopharmaceutical company focused on infectious diseases, reported its second quarter 2025 financial results. The company achieved total revenue of $10.7 million, which includes previously-deferred revenue following the reacquisition of Greater China rights to imdusiran. This represents a significant increase compared to the $1.7 million reported in the same period in 2024. The company reported a net income of $2.5 million for the quarter, in contrast to a net loss of $19.8 million in the second quarter of 2024. Arbutus also announced key updates in its corporate governance, with Dr. Roger Sawhney joining the Board of Directors following the resignation of Anuj Hasija, and Dr. Harry Janssen joining the Scientific Advisory Board. The company reported a strong financial position with cash, cash equivalents, and marketable securities totaling $98.1 million as of June 30, 2025. As of the same date, Arbutus had 191.6 million common shares issued and outstanding. No specific outlook or guidance was provided in the report.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Arbutus Biopharma Corp. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9506895-en) on August 06, 2025, and is solely responsible for the information contained therein.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment